Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) is now considered as a
standard treatment of locally advanced rectal adenocarcinomas, which correlates better local
control and higher sphincter preservation rate. Nimotuzumab, a humanized monoclonal antibody
against epidermal growth factor receptor (EGFR) has been reported to improve the therapeutic
effect of radiotherapy in some cancers. This study is a clinical phase II trial designed to
evaluate the efficacy of the combination of Nimotuzumab administered concurrently with
neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer, and to further
investigate its side-effect and toxicity.